Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
Yungan Tao, J. Biau, X.S. Sun, Clément Sire, Laurent Martin, M. Alfonsi, J.B. Prevost, A. Modesto, C. Lafond, J.M. Tourani, J. Miroir, Marie‐Christine Kaminsky, Alexandre Coutté, X. Liem, Emmanuel Chautard, Élodie Vauléon, Franck Drouet, Amandine Ruffier, Jean‐François Ramée, G. Waksi, Adeline Péchery, M. Wanneveich, J. Guigay, A. Aupérin, Jean Bourhis
Topics & Concepts
MedicineCetuximabCisplatinPembrolizumabHead and neck cancerOncologyHead and neck squamous-cell carcinomaRadiation therapyHead and neckRandomized controlled trialInternal medicineBasal cellChemotherapySurgeryCancerImmunotherapyColorectal cancerHead and Neck Cancer StudiesEsophageal Cancer Research and TreatmentCancer Immunotherapy and Biomarkers